ReviewFrontiers in oncology2026
Recombinant adenoviruses application for cancer vaccines: from genetic design to clinical translation.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health challenge, with conventional therapies often limited by toxicity and insufficient efficacy. Oncolytic virotherapy has emerged as a promising immunotherapeutic approach, utilizing genetically engineered viruses to selectively target and destroy cancer cells while stimulating anti-tumor immune responses. Among various oncolytic viruses, adenoviruses (HAdVs) have been extensively studied due to their ability to be genetically modified for enhanced tumor selectivity and immunogenicity. This review explores the mechanisms by which adenovirus vectors function as cancer immunotherapies, detailing their genetic modifications to improve tumor targeting, replication, and immune activation. Additionally, we highlight key clinical trials that have evaluated adenovirus-based therapies in different cancer types, emphasizing their efficacy, safety, and potential for future therapeutic applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.